Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
about
Novel biomarkers for pulmonary arterial hypertensionAdvances in the prevention, management, and treatment of community-acquired pneumoniaEndothelin-1 and its role in the pathogenesis of infectious diseasesMeta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infectionsBiomarkers in community-acquired pneumonia: a state-of-the-art reviewFailure of CRP decline within three days of hospitalization is associated with poor prognosis of Community-acquired PneumoniaTools for outcome prediction in patients with community acquired pneumonia.Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical PneumoniaRisk stratification in emergency patients by copeptinLong-term prognosis in community-acquired pneumonia.How and when to use common biomarkers in community-acquired pneumoniaInterleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZSerum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort studyInflammatory parameters and prediction of prognosis in infective endocarditisPneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study.The incidence of cardiovascular events after hospitalization due to CAP and their association with different inflammatory markers.Defining severe pneumonia.Management of severe community-acquired pneumonia in Brazil: a secondary analysis of an international surveyWhat procalcitonin brings to management of sepsis in the ICU.Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.Update in pulmonary infections 2010.Risk Factors for Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study.A mortality prediction rule for non-elderly patients with community-acquired pneumoniaPrognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE studyInflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio.Cardiorenal biomarkers in acute heart failure.Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29)Clinical significance of dynamic monitoring of blood lactic acid, oxygenation index and C-reactive protein levels in patients with severe pneumonia.Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.Pro-adrenomedullin, pro-endothelin-1, procalcitonin, C-reactive protein and mortality risk in critically ill children: a prospective study.Copeptin and its potential role in diagnosis and prognosis of various diseases.Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.Biomarkers in community-acquired pneumonia.[CAPNETZ. The competence network for community-acquired pneumonia (CAP)].MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.A pilot study on the diagnostic accuracy of proadrenomedullin and proatrial natriuretic Peptide in lower respiratory tract infections.Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity.Is N-terminal pro-B-type natriuretic peptide ready for 'prime time' in severe pneumonia?
P2860
Q26738666-EF17E350-8E6F-46C5-8134-77CD362F1A7AQ26753138-1A47B8BD-14E5-4100-81E0-ADA44F99DC1DQ26830339-E16ACC26-5560-4261-ADB2-E64DCE120399Q27023057-46876B2B-7C5E-4269-85B6-6AB61A142883Q27026995-0DE34E62-906F-49ED-A9FB-8BF88AB6A50FQ30160730-5A79527A-623C-46F5-B951-C62424CC4841Q30240254-377A3F21-843A-4BD0-96E2-FDB05D8A5DAFQ33714041-76B709AF-3808-473A-A0DD-2A3A440EB094Q33740059-5B4A392B-8CCE-4230-836A-791A220269AAQ33790638-B49DAECF-6879-4EA4-9692-A5197097756DQ33801313-A645A30D-11BD-4D06-8A81-F08D9CF276A5Q34164151-0B280314-570E-4D13-B2CD-3C1974847D30Q34231948-BA6258D9-B1B2-4EAB-8523-9B8B9F162909Q34773437-2A6D9A02-0375-4C2F-B274-6F5377020AF8Q35007069-83034D71-3929-4C3B-8876-B70697261FB8Q35060159-4FB0B531-DF2F-44FD-8641-D03F2707E41CQ35184605-876D9295-A3CF-427D-B39E-89D6BADE71D3Q35414633-5ABCF909-9EDE-4B10-92C8-52214A9E22A9Q35561389-F9CC349E-1D38-4DC0-869A-EC1B7FACE531Q35648136-BC7A7AD4-BF64-4883-B70B-DDE2680D2D87Q35692215-3AAD3DB3-31E9-4585-8BAF-0F7CD949166DQ35915851-4433E840-C77A-41F4-8D3C-82D296737B67Q35949943-79EF0D3C-1DA9-4FD1-82F7-44F2AFF1B323Q36031663-507039B0-4720-440C-A9CC-31B48967D185Q36222704-F78DAA19-BF32-4940-9425-C6B063D2A062Q36310667-EAA57BAF-C62C-4594-8472-34EECCAE2B20Q36313675-470AAD86-0F63-4A91-86AE-318CF0B59755Q36334718-6C388F19-4C98-4091-AD8B-E7187C720B79Q36335565-1D4AA487-DA66-47F2-9495-0172F93E3636Q37209299-FBAA9457-27F8-4FBB-9BDA-037FAE099B3FQ37343247-2D5015CD-B8E1-4D5E-9D27-A225592919B8Q37508425-CB705FAA-0D4E-4F6C-B75E-A4CAA9B41AF5Q37870823-60EADB16-B340-4F61-9ED2-2CA8907DF0DFQ37997820-42A08194-FC65-4F2A-B17C-9EBCB23701A7Q38382078-22052371-5803-48AE-A51B-5206DC3EE1C0Q40989235-245361A8-A3BA-43C4-9035-9D223556E49DQ41368070-BEC00CA0-9B85-4210-BA88-101E6AF037D6Q42078185-F8A097DB-70EB-489A-9A2C-6AA4DFEA043FQ42321773-BD3DCCB4-D958-4977-A84A-C7B32DEDA558Q42721096-B84A070B-87DE-44E1-90EA-934083BDC46C
P2860
Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@en
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@nl
type
label
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@en
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@nl
prefLabel
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@en
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@nl
P2093
P2860
P921
P1476
Cardiovascular and inflammator ...... n Competence Network, CAPNETZ.
@en
P2093
German Competence Network for ...... neumonia (CAPNETZ) Study Group
Norbert Suttorp
Oliver Hartmann
Santiago Ewig
Stefan Krüger
Sven Giersdorf
P2860
P304
P356
10.1164/RCCM.201003-0415OC
P407
P50
P577
2010-07-16T00:00:00Z